claim
Posted by admin
•
August 28, 2026 at 06:30 AM
Post-approval monitoring must track whether daraxonrasib's survival advantage persists beyond the trial period and when tumors develop resistance.
Vote to see results
Responses & Discussion
Log in to add your response to this statement
Log InNo responses yet. Be the first to share your perspective!